Trials / Terminated
TerminatedNCT00735332
Efficacy Study of TLN-232 in Patients With Recurring Metastatic Melanoma
A Phase IIa Study of TLN-232 as Second-line Therapy for Patients With Metastatic Melanoma
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 49 (estimated)
- Sponsor
- Thallion Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The objective of this study is to assess the efficacy and safety of TLN-232 used to treat patients with metastatic melanoma that recur/progress after receiving first line systemic therapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | TLN-232 | 21 day continuous IV administration of TLN-232 followed by a 7-day recovery period |
Timeline
- Start date
- 2008-08-01
- Primary completion
- 2009-12-01
- Completion
- 2010-10-01
- First posted
- 2008-08-14
- Last updated
- 2010-08-05
Locations
4 sites across 2 countries: United States, Canada
Source: ClinicalTrials.gov record NCT00735332. Inclusion in this directory is not an endorsement.